Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.97 +0.3%	$4.53	$3.21 ▼ $8.06	$949.84M	0.76	4.46 million shs	2.57 million shs
COLL Collegium Pharmaceutical	$28.86 +0.1%	$28.11	$23.23 ▼ $42.29	$927.33M	0.63	427,547 shs	178,265 shs
PAHC Phibro Animal Health	$23.24 +1.0%	$20.29	$16.16 ▼ $26.55	$942.01M	0.62	198,566 shs	135,439 shs
TNGX Tango Therapeutics	$1.84 -1.3%	$1.46	$1.03 ▼ $12.02	$199.45M	1.02	1.26 million shs	2.43 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+0.25%	+2.32%	-18.14%	-21.46%	-49.23%
COLL Collegium Pharmaceutical	+0.14%	-4.53%	+11.04%	-0.93%	-15.56%
PAHC Phibro Animal Health	+0.96%	-3.17%	+35.12%	+3.29%	+26.24%
TNGX Tango Therapeutics	-1.34%	+22.67%	+25.17%	-22.03%	-75.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.3887 of 5 stars	4.5	2.0	0.0	4.4	1.9	2.5	0.6
COLL Collegium Pharmaceutical	4.023 of 5 stars	3.4	0.0	0.0	3.0	4.0	0.8	2.5
PAHC Phibro Animal Health	3.4767 of 5 stars	0.8	3.0	2.5	1.1	2.9	3.3	2.5
TNGX Tango Therapeutics	1.8629 of 5 stars	3.5	0.0	0.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.90	Moderate Buy	$10.39	161.68% Upside
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.80	51.77% Upside
PAHC Phibro Animal Health	1.50	Reduce	$20.00	-13.94% Downside
TNGX Tango Therapeutics	3.00	Buy	$12.20	563.04% Upside

Current Analyst Ratings Breakdown

Latest TNGX, PAHC, ARDX, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/12/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
3/7/2025	ARDX Ardelyx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00
3/7/2025	ARDX Ardelyx	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$11.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$361.71M	2.63	N/A	N/A	$0.73 per share	5.44
COLL Collegium Pharmaceutical	$664.28M	1.40	$10.46 per share	2.76	$5.99 per share	4.82
PAHC Phibro Animal Health	$1.19B	0.79	$2.14 per share	10.87	$6.09 per share	3.82
TNGX Tango Therapeutics	$40.99M	4.87	N/A	N/A	$2.48 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	12.81	N/A	-11.73%	-24.87%	-10.51%	8/7/2025 (Estimated)
COLL Collegium Pharmaceutical	$48.15M	$1.22	12.44	4.79	N/A	14.78%	104.67%	18.38%	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	48.42	11.07	0.45	1.75%	25.35%	6.21%	N/A
TNGX Tango Therapeutics	-$101.74M	-$1.22	N/A	N/A	N/A	-284.42%	-49.64%	-32.00%	8/6/2025 (Estimated)

Latest TNGX, PAHC, ARDX, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million
2/27/2025	Q4 2024	COLL Collegium Pharmaceutical	$1.54	$1.63	+$0.09	$0.36	$179.68 million	$181.95 million
2/27/2025	Q4 2024	TNGX Tango Therapeutics	-$0.32	-$0.35	-$0.03	-$0.35	$7.84 million	$4.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.07%	N/A	61.54%	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest TNGX, PAHC, ARDX, and COLL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	0.87	4.58	4.31
COLL Collegium Pharmaceutical	3.43	0.97	0.88
PAHC Phibro Animal Health	2.99	3.20	1.37
TNGX Tango Therapeutics	N/A	8.00	8.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
COLL Collegium Pharmaceutical	N/A
PAHC Phibro Animal Health	99.34%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
COLL Collegium Pharmaceutical	2.51%
PAHC Phibro Animal Health	50.07%
TNGX Tango Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	222.88 million	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.22 million	Optionable
TNGX Tango Therapeutics	90	108.39 million	100.65 million	Optionable

TNGX, PAHC, ARDX, and COLL Headlines

Recent News About These Companies

Tango Therapeutics starts trial for brain cancer drug

May 23 at 11:17 AM | uk.investing.com

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 21 at 7:00 AM | globenewswire.com

517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.

May 19, 2025 | marketbeat.com

Q2 EPS Estimate for Tango Therapeutics Increased by Analyst

May 17, 2025 | marketbeat.com

Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 17, 2025 | marketbeat.com

Leerink Partnrs Brokers Boost Earnings Estimates for TNGX

May 17, 2025 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price

May 16, 2025 | finance.yahoo.com

Orbimed Advisors LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 15, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPS

May 14, 2025 | marketbeat.com

Analyzing Tango Therapeutics (NASDAQ:TNGX) and Rosetta Genomics (OTCMKTS:ROSGQ)

May 14, 2025 | americanbankingnews.com

Tango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline Developments

May 14, 2025 | nasdaq.com

Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13, 2025 | finanznachrichten.de

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13, 2025 | finance.yahoo.com

Tango Therapeutics Extends Cash Runway Amid Clinical Progress

May 13, 2025 | tipranks.com

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 12, 2025 | globenewswire.com

4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLC

May 11, 2025 | marketbeat.com

Balyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 11, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by Analysts

May 11, 2025 | marketbeat.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday

May 7, 2025 | marketbeat.com

Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

May 5, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX, PAHC, ARDX, and COLL Company Descriptions

Ardelyx NASDAQ:ARDX

$3.97 +0.01 (+0.25%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$3.96 -0.01 (-0.13%)

As of 05/23/2025 06:58 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Collegium Pharmaceutical NASDAQ:COLL

$28.86 +0.04 (+0.14%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$28.80 -0.06 (-0.22%)

As of 05/23/2025 05:44 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$23.24 +0.22 (+0.96%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$23.22 -0.02 (-0.09%)

As of 05/23/2025 04:04 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Tango Therapeutics NASDAQ:TNGX

$1.84 -0.03 (-1.34%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.86 +0.02 (+1.36%)

As of 05/23/2025 07:43 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time